FLUO Stock Overview
A clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
FluoGuide A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 39.20 |
52 Week High | SEK 99.80 |
52 Week Low | SEK 38.80 |
Beta | 1.07 |
11 Month Change | -6.89% |
3 Month Change | -17.82% |
1 Year Change | -57.67% |
33 Year Change | -65.61% |
5 Year Change | 639.62% |
Change since IPO | 607.58% |
Recent News & Updates
Recent updates
Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth
Jan 27FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans
Oct 07We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely
May 21FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans
Jan 31Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth
Feb 25Shareholder Returns
FLUO | SE Biotechs | SE Market | |
---|---|---|---|
7D | -6.2% | -2.4% | -4.3% |
1Y | -57.7% | 18.0% | 12.6% |
Return vs Industry: FLUO underperformed the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: FLUO underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
FLUO volatility | |
---|---|
FLUO Average Weekly Movement | 5.4% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: FLUO's share price has been volatile over the past 3 months.
Volatility Over Time: FLUO's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 8 | Morten Albrechtsen | fluoguide.com |
FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology.
FluoGuide A/S Fundamentals Summary
FLUO fundamental statistics | |
---|---|
Market cap | SEK 533.50m |
Earnings (TTM) | -SEK 56.24m |
Revenue (TTM) | SEK 592.36k |
900.6x
P/S Ratio-9.5x
P/E RatioIs FLUO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FLUO income statement (TTM) | |
---|---|
Revenue | DKK 383.00k |
Cost of Revenue | DKK 0 |
Gross Profit | DKK 383.00k |
Other Expenses | DKK 36.75m |
Earnings | -DKK 36.36m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | -2.67 |
Gross Margin | 100.00% |
Net Profit Margin | -9,494.26% |
Debt/Equity Ratio | 177.8% |
How did FLUO perform over the long term?
See historical performance and comparison